Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Assessment of Hydroxychloroquine and Chloroquine Safety Profiles – A Systematic Review and Meta-Analysis

View ORCID ProfileLu Ren, Wilson Xu, James L Overton, Shandong Yu, View ORCID ProfileNipavan Chiamvimonvat, View ORCID ProfilePhung N. Thai
doi: https://doi.org/10.1101/2020.05.02.20088872
Lu Ren
1Department of Internal Medicine, Cardiology, UC Davis
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Lu Ren
Wilson Xu
1Department of Internal Medicine, Cardiology, UC Davis
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James L Overton
1Department of Internal Medicine, Cardiology, UC Davis
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shandong Yu
3Department of Cardiology, Cardiovascular Center, Beijing Friendship Hospital, Capital Medical University, Beijing
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nipavan Chiamvimonvat
1Department of Internal Medicine, Cardiology, UC Davis
2Department of Veteran Affairs
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Nipavan Chiamvimonvat
  • For correspondence: pnthai@ucdavis.edu nchiamvimonvat@ucdavis.edu
Phung N. Thai
1Department of Internal Medicine, Cardiology, UC Davis
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Phung N. Thai
  • For correspondence: pnthai@ucdavis.edu nchiamvimonvat@ucdavis.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Recently, chloroquine (CQ) and its derivative hydroxychloroquine (HCQ) have emerged as potential antiviral and immunomodulatory options for the treatment of 2019 coronavirus disease (COVID-19). To examine the safety profiles of these medications, we systematically evaluated the adverse events (AEs) of these medications from published randomized controlled trials (RCTs).

Methods We systematically searched PubMed, MEDLINE, Cochrane, the Cochrane Central Register of Controlled Trials (CENTRAL), EMBASE, and the ClinicalTrials.gov for all the RCTs comparing CQ or HCQ with placebo or other active agents, published before March 31, 2020. The random-effects or fixed-effects models were used to pool the risk estimates relative ratio (RR) with 95% confidence interval (CI) for the outcomes.

Results The literature search yielded 23 and 17 studies for CQ and HCQ, respectively, that satisfied our inclusion criteria. Of these studies, we performed meta-analysis on the ones that were placebo-controlled, which included 6 studies for CQ and 14 studies for HCQ. We did not limit our analysis to published reports involving viral treatment alone; data also included the usage of either CQ or HCQ for the treatment of other diseases. The trials for the CQ consisted of a total of 2,137 participants (n=1,077 CQ, n=1,060 placebo), while the trials for HCQ involved 1,096 participants (n=558 HCQ and n=538 placebo). The overall mild or total AEs were statistically higher comparing CQ or HCQ to placebo. The AEs were further categorized into four groups and analyses revealed that neurologic, gastrointestinal, dermatologic, and ophthalmic AEs were higher in participants taking CQ compared to placebo. Although this was not evident in HCQ treated groups, further analyses suggested that there were more AEs attributed to other organ system that were not included in the categorized meta-analyses. Additionally, meta-regression analyses revealed that total AEs was affected by dosage for the CQ group.

Conclusions Taken together, we found that participants taking either CQ or HCQ have more AEs than participants taking placebo. Precautionary measures should be taken when using these drugs to treat COVID-19.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work was supported by American Heart Association Predoctoral Award 18PRE34030199 (LR); Postdoctoral Fellowship from NIH F32 HL149288 (PNT); NIH R01 HL085727, HL085844, HL137228, and S10 RR033106, Research Award from the Rosenfeld Foundation, VA Merit Review Grant I01 BX000576 and I01 CX001490 (NC).

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Corresponding authors can provide data upon request.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted May 08, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Assessment of Hydroxychloroquine and Chloroquine Safety Profiles – A Systematic Review and Meta-Analysis
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Assessment of Hydroxychloroquine and Chloroquine Safety Profiles – A Systematic Review and Meta-Analysis
Lu Ren, Wilson Xu, James L Overton, Shandong Yu, Nipavan Chiamvimonvat, Phung N. Thai
medRxiv 2020.05.02.20088872; doi: https://doi.org/10.1101/2020.05.02.20088872
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Assessment of Hydroxychloroquine and Chloroquine Safety Profiles – A Systematic Review and Meta-Analysis
Lu Ren, Wilson Xu, James L Overton, Shandong Yu, Nipavan Chiamvimonvat, Phung N. Thai
medRxiv 2020.05.02.20088872; doi: https://doi.org/10.1101/2020.05.02.20088872

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Pharmacology and Therapeutics
Subject Areas
All Articles
  • Addiction Medicine (62)
  • Allergy and Immunology (142)
  • Anesthesia (47)
  • Cardiovascular Medicine (416)
  • Dentistry and Oral Medicine (70)
  • Dermatology (49)
  • Emergency Medicine (146)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (171)
  • Epidemiology (4875)
  • Forensic Medicine (3)
  • Gastroenterology (183)
  • Genetic and Genomic Medicine (678)
  • Geriatric Medicine (70)
  • Health Economics (192)
  • Health Informatics (633)
  • Health Policy (322)
  • Health Systems and Quality Improvement (208)
  • Hematology (85)
  • HIV/AIDS (156)
  • Infectious Diseases (except HIV/AIDS) (5362)
  • Intensive Care and Critical Care Medicine (332)
  • Medical Education (94)
  • Medical Ethics (24)
  • Nephrology (75)
  • Neurology (690)
  • Nursing (42)
  • Nutrition (115)
  • Obstetrics and Gynecology (127)
  • Occupational and Environmental Health (209)
  • Oncology (443)
  • Ophthalmology (140)
  • Orthopedics (36)
  • Otolaryngology (90)
  • Pain Medicine (35)
  • Palliative Medicine (17)
  • Pathology (130)
  • Pediatrics (196)
  • Pharmacology and Therapeutics (131)
  • Primary Care Research (84)
  • Psychiatry and Clinical Psychology (782)
  • Public and Global Health (1824)
  • Radiology and Imaging (325)
  • Rehabilitation Medicine and Physical Therapy (138)
  • Respiratory Medicine (255)
  • Rheumatology (86)
  • Sexual and Reproductive Health (69)
  • Sports Medicine (62)
  • Surgery (102)
  • Toxicology (23)
  • Transplantation (29)
  • Urology (37)